#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Patient with generalized malignant melanoma treated with nivolumab in the first line

A 75-year-old patient was referred for examination at the dermato-oncology clinic of the Dermatology Clinic of VFN in September 2016. He was being treated for ICHS and had undergone prostate surgery for hyperplasia in 2013.
Source: Case Studies from Immunooncology 10. 9. 2020

News Patient with Generalized Melanoma Treated with Nivolumab with Long-Term Response after Previous Failure of Combined Chemoimmunotherapy

Source: Case Studies from Immunooncology 11. 9. 2020

News Effective Treatment with Nivolumab in Patients with Negative PD-L1 Expression

Source: Case Studies from Immunooncology 11. 5. 2020

News Thyroid Disease as a Side Effect of Nivolumab

Source: Case Studies from Immunooncology 4. 2. 2020

News Focus on the Connections Between Gastroesophageal Reflux Disease and COPD Exacerbations

In recent years, evidence has emerged of a higher prevalence of gastroesophageal reflux disease (GERD) in patients with chronic obstructive pulmonary disease (COPD). GERD symptoms are more common in them, especially in patients with severe COPD and frequent exacerbations. Why is this, and what direct links can be traced between the two diseases?
Source: Treatment of Asthma and COPD 1. 9. 2020

News Digital Technology in COPD Therapy: Current Options and Future Prospects

This year, digital technologies have demonstrated their advantages in interpersonal communication, administrative processes, and in the field of medicine. The global crisis triggered by the coronavirus pandemic revealed the need to implement telemedicine into everyday medical practice. What are its options and future prospects in the therapy of patients with chronic obstructive pulmonary disease? These questions are thoroughly addressed in an article published in the Journal of Thoracic Disease last fall.
Source: Treatment of Asthma and COPD 1. 9. 2020

News Sport and Programmed Sports Therapy in Hemophiliacs

Sport and physical activity are increasingly becoming an integrated part of the treatment plan for hemophiliacs. It was not long ago that sports were almost forbidden for these patients. The possibilities for active movement were determined by the availability of effective treatment. It has also become clear that sport is not just sport but to some extent also part of the treatment –⁠ thanks to the care of experienced physiotherapists.
Source: Hemophilia with Movement 2. 9. 2020

News Physical Activity in Hemophiliacs and How to Ensure it Safely

Physical activity is beneficial −⁠ and this holds true for patients with hemophilia as well. New therapeutic modalities offer additional possibilities to optimize prevention so that, among other things, it allows hemophiliacs to engage in sports.
Source: Hemophilia with Movement 2. 9. 2020

News Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients

Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis strategies have been studied in morbidly obese patients; a recently published study compared the efficacy and safety of high doses of enoxaparin and unfractionated heparin.
Source: Thromboprophylaxis 28. 1. 2020

News Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity

Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often associated with subprophylactic anti-Xa activity in high-risk patients. A recently published study evaluated the efficacy and safety of administering enoxaparin in doses adjusted according to the measured anti-Xa activity.
Source: Thromboprophylaxis 28. 1. 2020

News Inflammation, Polyunsaturated Fatty Acids and Their Significance in the Development and Treatment of Depression

Depression is currently a highly discussed disease with a prevalence that is likely to rise. Therefore, scientists are focusing on potential causes and new treatment modalities. It has been shown that inflammation, which can be influenced by polyunsaturated fatty acids, likely plays a role in the development of the disease. Inflammation is also a possible explanation for the frequent coexistence of depression and metabolic syndrome.
Source: Depression and Anxiety 19. 7. 2020

News Aclidinium bromide improves the quality of life for COPD patients

The ON-AIR study conducted in real practice demonstrated the benefits of aclidinium bromide for the quality of life of patients with chronic obstructive pulmonary disease (COPD). It also assessed the impact of treatment on the severity of nocturnal and morning symptoms and their impact on daily activities.
Source: Treatment of Asthma and COPD 15. 7. 2020

News Study AMPLIFY Confirmed Safety and Efficacy of Fixed Combination Aclidinium/Formoterol in COPD Therapy

The randomized double-blind phase III AMPLIFY study compared the efficacy of a fixed combination of formoterol/aclidinium with monotherapy of the individual components or with tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Source: Treatment of Asthma and COPD 15. 7. 2020

News Efficacy of L. reuteri DSM 17938 in Treating Acute Gastroenteritis in Children

Diarrheal diseases are among the most common causes of death worldwide in children under 5 years of age. Effective and timely treatment is crucial in the case of acute gastroenteritis (AGE), which is why probiotics are attracting significant attention in the context of AGE therapy. A meta-analysis published last year in the journal Nutrients focused on the efficacy of Lactobacillus reuteri DSM 17938 in treating AGE in children from 3 months to 5 years old.
Source: GI, colic and microbiome 15. 7. 2020

News New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?

The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly expanded in recent years. Significant changes have been brought particularly by small molecule-based therapeutic agents (inhibitors), which have shown significant efficacy in both previously untreated patients and those who have relapsed from CLL. When choosing the best treatment strategy for patients with CLL, it is of course necessary to consider the specific adverse effects of both new and previously used drugs, the overall condition of the patient, comorbidities, and the so-called individual risk of serious side effects of the drugs.
Source: Chronic Lymphocytic Leukemia 13. 3. 2020

1 81 82 83 84 85 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#